TABLE 3.
Long‐term survivors with complete remission who were initiated on mogamulizumab plus intensive chemotherapy between December 2010 and December 2018
| Treatment regimen | N |
|---|---|
| Mogamulizumab plus EPOCH | 22 |
| Mogamulizumab plus VCAP‐AMP‐VECP (mLSG15) | 14 |
| Mogamulizumab plus CHOP‐like | 2 |
| Number of patients | Sex | Age at diagnosis | Subtype of ATLL | Survival after starting chemotherapy (months) | CD4/CD8 reversal | Herpes virus infection | HLA |
|---|---|---|---|---|---|---|---|
| 7 | Male | 78 | Acute | >47 | + | + |
A*02:01 A*24:02 |
| 8 | Female | 62 | Acute | >41 | + | + | A*24:02 |
| 9 | Female | 69 | Acute | >37 | + | − | A*02:01 |
| 10 | Female | 80 | Lymphoma | >55 | + | + |
A*26:03 A*31:01 |
Abbreviations: ATLL, adult T‐cell leukemia/lymphoma; HLA, human leukocyte antigen.